Proteo (OTCMKTS:PTEO) is a biotechnology company specializing in advanced proteomics research and the development of diagnostic and therapeutic solutions. The company leverages proprietary mass spectrometry and bioinformatics platforms to identify and quantify protein biomarkers associated with a wide range of diseases, including oncology, neurodegenerative disorders, and inflammatory conditions. Through its core technology, Proteo aims to enable earlier and more precise disease detection, monitor treatment efficacy, and accelerate the discovery of new drug targets.
Proteo’s product offerings include its flagship ProteoScan™ mass spectrometry system, a high-throughput platform designed for clinical and research laboratories. Alongside its instrumentation suite, the company provides custom assay development services, enabling pharmaceutical partners to integrate Proteo’s biomarker panels into their drug development pipelines. Proteo also offers contract research services (CRO) for proteomic profiling studies, supporting both preclinical and clinical trial phases. These integrated capabilities position the company at the intersection of diagnostics, research, and therapeutic innovation.
Founded in 2012 as a spin-off from a leading academic proteomics center in Massachusetts, Proteo has expanded its operations globally over the past decade. Headquartered in Cambridge, Massachusetts, the company maintains research and manufacturing facilities in Germany and Singapore, serving a diverse client base across North America, Europe, and Asia. Strategic partnerships with major pharmaceutical corporations and academic institutions have bolstered Proteo’s presence in key markets, reflecting a commitment to collaborative development and technology transfer.
Under the leadership of CEO Dr. Maria Sanchez, Proteo’s management team brings together seasoned experts in proteomics, clinical diagnostics, and commercial development. Dr. Sanchez, who joined the company in 2018 following a tenure at a leading precision medicine firm, has overseen the launch of multiple biomarker panels and the expansion of Proteo’s global footprint. Supporting her are CFO John Miller, with extensive experience in life science financing, and Chief Scientific Officer Dr. Alan Peters, a pioneer in quantitative proteomics. Together, the leadership team is focused on advancing Proteo’s pipeline, fostering partnerships, and delivering next-generation solutions to the life sciences and healthcare sectors.
AI Generated. May Contain Errors.
Free PTEO Stock Alerts